FAPI PET/CT能否终结18F-FDG在肿瘤学中的霸主地位?
本文综述了靶向成纤维细胞激活蛋白(FAP)的小分子抑制剂类示踪剂在肿瘤学中的发展及初步临床数据,指出这类示踪剂在几乎所有正常组织中摄取低、在多数癌症类型中摄取高,并讨论了其潜在的非肿瘤应用。文章回顾了18F-FDG四十余年来在肿瘤等领域的统治地位及其优势与特异性不足的弱点,提出FAPI示踪剂可能改变现有格局。
要点
- 18F-FDG因广谱应用和高灵敏度长期主导肿瘤PET,但特异性受糖酵解增强的多种病理限制。
- FAPI类示踪剂靶向成纤维细胞激活蛋白,正常组织摄取低而多数癌症类型摄取高。
- 综述总结了FAPI小分子抑制剂类示踪剂的开发与初步临床数据,并提及潜在非肿瘤应用。
核心结论
- 靶向成纤维细胞激活蛋白的示踪剂因正常组织低摄取、多数癌症高摄取,可能对18F-FDG在肿瘤学中的主导地位构成竞争。
研究设计与样本
- 本文为综述,讨论靶向成纤维细胞激活蛋白的小分子抑制剂类示踪剂在肿瘤学中的开发与初步临床数据,并涉及潜在非肿瘤应用。
主要发现
- 18F-FDG已主导PET示踪剂四十余年,在肿瘤学中尤为突出,其优势在于无结构异常时检测疾病以提高诊断灵敏度。
- 18F-FDG的弱点是特异性不足,因多种病理均表现为糖酵解增强。
- 靶向其他癌症标志或特定细胞表面靶点的示踪剂正逐渐找到应用空间,但尚无足够灵敏度与18F-FDG在广谱恶性肿瘤评估中竞争。
- 靶向成纤维细胞激活蛋白的示踪剂在几乎所有正常组织中摄取低,在大多数癌症类型中摄取高。
临床怎么用
- FAPI PET/CT在正常组织低摄取而多数癌症高摄取的特点,提示其可能用于肿瘤评估,但需结合原文所述初步临床数据理解其当前定位。
局限性
- 原文为综述,讨论的是初步临床数据,未提供具体阈值、样本量或效应量等定量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology, inflammatory diseases, and, most particularly, oncology. Combined with the ability to perform whole-body scanning, 18F-FDG has revolutionized the evaluation of cancer and has stifled the adoption of other tracers, except in situations where low avidity or high background activity limits diagnostic performance. The strength of 18F-FDG has generally been its ability to detect disease in the absence of structural abnormality, thereby enhancing diagnostic sensitivity, but its simultaneous weakness has been a lack of specificity due to diverse pathologies with enhanced glycolysis. Radiotracers that leverage other hallmarks of cancer or specific cell-surface targets are gradually finding a niche in the diagnostic armamentarium. However, none have had sufficient sensitivity to realistically compete with 18F-FDG for evaluation of the broad spectrum of malignancies. Perhaps, this situation is about to change with development of a class of tracers targeting fibroblast activation protein that have low uptake in almost all normal tissues but high uptake in most cancer types. In this review, the development and exciting preliminary clinical data relating to various fibroblast activation protein-specific small-molecule inhibitor tracers in oncology will be discussed along with potential nononcologic applications.
引用
- Hicks RJ, Roselt PJ, Kallur KG, et al. FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology? J Nucl Med. 2020. PMID: 33277397. doi:10.2967/jnumed.120.256271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。